Brief: Kiromic Biopharma Expands Gamma Delta T Cell Product Pipeline With New Sponsored Research Agreement
07/06/2022 12:12
June 7 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA SIGNIFICANTLY EXPANDS GAMMA DELTA T CELL
PRODUCT PIPELINE WITH NEW SPONSORED RESEARCH AGREEMENT
* KIROMIC BIOPHARMA - UNDER TWO-YEAR SRA, IN VIVO
PRECLINICAL DATA
WILL BE GENERATED FROM KIROMIC'S GAMMA DELTA T CELL (GDT)
ALLOGENEIC THERAPIES
* KIROMIC BIOPHARMA - SRA INTENDED TO EVALUATE EFFICACY AND
PATIENT SAFETY OUTCOMES TO SUPPORT THREE NEW INVESTIGATIONAL
DRUG (IND) APPLICATIONS TO FDA
Source text for Eikon: ID:nBw6S5WYha
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site